One Man at a Time — Resolving the PSA Controversy
Ces deux articles analysent les récentes recommandations d'un groupe d'experts américains, l'U.S. Preventive Services Task Force, sur l'intérêt du dosage de l'antigène spécifique de la prostate pour la détection d'un cancer chez les hommes asymptomatiques
Who should decide about screening for prostate cancer: expert panels of clinicians and methodologists, primary care clinicians, specialists, or fully informed patients themselves?
The U.S. Preventive Services Task Force recently released a draft recommendation on screening for prostate cancer, designed for primary care physicians and health systems, and has opened it for public comment until November 8, 2011.1 After completing a rigorous evidence review, the task force decided to recommend against screening for prostate-specific antigen (PSA), concluding that there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. This grade D recommendation applies to healthy men of all ages, regardless of race or family history. The task force's suggestion for practice for grade D interventions is to “discourage the use of this service.”....
New England Journal of Medicine , article en libre accès, 2010